[en] Introduction: Psoriasis is a hereditary, inflammatory and chronic skin disease, with a worldwide prevalence of approximately 1% to 3%. The cutaneous presentation of this pathology is usually characterized by well-defined lesions with typical white-pearly scales. Moreover, there is a great variability in morphology and severity. It is considered that between 80% and 90% of patients with psoriasis will develop lesions derived from the disease in the nails, affecting both the matrix and the nail bed. For the management of nail psoriasis there are different therapeutic options and different routes of administration, including enteral, parenteral and topical administration. Objectives: To review the efficacy of the main existing treatments for nail disorders derived from psoriasis. Methods: A review the scientific literature, including 4 scientific databases: Pubmed, Cochrane, Dialnet and Scopus, to analyze which the most effective treatments for the treatment of nail psoriasis was performed. After the search and subsequent reading of the articles, 22 articles, which fitted the proposed inclusion criteria were selected. Results: In the articles, the effectiveness of the different existing therapies for the treatment of nail psoriasis at different times has been evaluated, with the range of effectiveness of the different active principles between 23% and 75%. In the topical administration, the most effective active ingredient has been Hydroxypropyl-chitosan with 50% efficacy at week 16. In the systemic administration, the most effective drug in conventional therapy has been Methotrexate with a 43% efficacy in the week 24. While, in the biological therapy the most effective active ingredient with 75%, was Certolizumab pegol at 24 weeks. Conclusion: Mild psoriasis is usually managed with topical treatments, highlighting the effectiveness of Hydroxypropyl-Chitosan. In moderate psoriasis, treatment can be systemic with the use of active substances such as Methotrexate and Cyclosporine. And in severe psoriasis, the use of biological treatments stands out, being the most commonly used inhibitors of tumor necrosis alpha where Certolizumab pegol showed the highest efficacy observed. There is the need for a greater number of comparative studies between the biologic therapy drugs.

[gl] Introdución: A psoriase é una enfermidade cutánea hereditaria, inflamatoria e crónica, cunha prevalencia mundial de aproximadamente entre o 1% e o 3%. A presentación cutánea da patoloxía caracterízase habitualmente por lesións ben definidas con escaras típicas blanco-nacaradas; existindo una gran variabilidade na morfoloxía e severidade. Considerase que entre o 80% e o 90% dos pacientes con psoriase chegarán a presentar lesións derivadas da patoloxía nas uñas, afectando tanto a nivel da matriz como do leito ungueal. Para o manexo da psoriase das uñas existen diferentes opcións terapéuticas e diferentes vías de administración tanto enterais como parenterais e tópicas. Obxetivos: Propúxose coñecer a eficacia dos principais tratamentos existentes para as alteracións ungueais derivadas da psoriase. Metodoloxía: Esta revisión ten como obxecto examinar a literatura científica para analizar cal ou cales son os tratamentos máis efectivos para o tratamento da psoríase ungueal. Para isto, realizouse una busca en 4 bases de datos científicas: Pubmed, Cochrane, Dialnet e Scopus. Tras a busca e posterior lectura dos artigos, seleccionáronse 22 artigos que cumprían os criterios de inclusión. Resultados: Nos artigos evaluouse a eficacia das diferentes terapias existentes para o tratamento da psoriase ungueal a diferentes tempos, sendo o rango de eficacia dos diferentes principios activos entre o 23% e o 75%. Na vía tópica o principio activo máis eficaz foi o Hidroxipropil-quitosano cun 50% de eficacia na semana 16. Na vía sistémica, o fármaco máis eficaz da terapia convencional foi o Metotrexato cun 43% de eficacia na semana 24. Mentres que, na terapia biolóxica o principio activo mais eficaz cun 75%, foi o Certolizumab pegol as 24 semanas. Conclusións: A psoriase leve manexase habitualmente con tratamentos tópicos onde destaca a eficacia do Hidroxipropil-quitosano. Na psoriase moderada o tratamento pode ser sistémico co uso de principios activos como o Metotrexaro e a Ciclosporina. E na psoríase grave destaca o uso de tratamentos biolóxicos, sendo os mais empregados os inhibidores da necrose tumoral alfa onde o Certolizumab pegol demostrou a maior eficacia observada. Observouse a necesidade de realizar un maior número de estudios comparativos entre os fármacos da terapia biolóxica.